Clinical, humanistic, and economic outcomes of gout.
Gout is a low prevalence disease not often considered by managed care organizations with regard to cost management. Understanding the development of the disease and its potential long-term, high-cost consequences can lead to appropriate treatment strategies and cost-management opportunities that can improve patient outcomes and potentially lower the overall cost of treatment of patients with gout in a managed care organization. The acute and chronic nature of the disease is best managed up front to avoid negative long-term effects. Adherence to medications can also impact the manifestation of the disease.
Brixner
Diana I
DI
Ho
Mei-Jen
MJ
D000328:Adult; D000368:Aged; D015984:Causality; D017281:Cost of Illness; D019468:Disease Management; D005260:Female; D014943:Global Health; D006073:Gout / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D006074:Gout Suppressants / Q000627:therapeutic use; D015438:Health Behavior; D006801:Humans; D033461:Hyperuricemia / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011788:Quality of Life
D006074:Gout Suppressants